TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3529884

Group type: EXPERIMENTAL
Intervention: Diclofenac alone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Aspirin + Diclofenac
Number of subjects: 36

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 36
Study: 29573375

Group type: EXPERIMENTAL
Intervention: 4% articaine with buccal intrapapillary infiltration
Number of subjects: 98

Group type: COMPARATOR
Intervention: 2% lidocaine with inferior dental nerve block and long buccal infiltration
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both interventions (4% articaine and 2% lidocaine)
Number of subjects: 98
Study: 27852621

Group type: EXPERIMENTAL
Intervention: Supervised physiotherapy
Number of subjects: 503

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 503
Study: 24404799

Group type: EXPERIMENTAL
Intervention: Daily preventive asthma medication prescribed (current prescription)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Caregiver-reported complete concordance
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Symptom severity (measured by symptom-free days)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Asthma-related hospitalization in the prior year
Number of subjects: 310
Study: 23957340

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 (6 × 10(9) cfu/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bifidobacterium animalis subsp lactis HN019 (9 × 10(9) cfu/day)
Number of subjects: 0
Study: 20682572

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 71

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with sedation
Number of subjects: 71

Group type: COMPARATOR
Intervention: Recovery room after General anaesthesia
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Recovery room after Spinal anaesthesia
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Recovery room after Spinal anaesthesia with sedation
Number of subjects: 71
Study: 19067498

Group type: EXPERIMENTAL
Intervention: Intervention group (decreased copayments for simvastatin)
Number of subjects: 13319

Group type: COMPARATOR
Intervention: Control group (standard copayments for non-simvastatin statins)
Number of subjects: 13319

Group type: EXPERIMENTAL
Intervention: Elasticity of demand for statins with copayment reduction of $0 to $5
Number of subjects: 13319

Group type: EXPERIMENTAL
Intervention: Elasticity of demand for statins with copayment reduction of >$15
Number of subjects: 13319
Study: 16548349

Group type: EXPERIMENTAL
Intervention: Wuling pill (WLP) plus conventional therapy
Number of subjects: 90
Study: 12963608

Group type: COMPARATOR
Intervention: Verteporfin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluorescein angiography
Number of subjects: 0
Study: 11007214

Group type: EXPERIMENTAL
Intervention: PDT (Photodynamic Therapy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PDT using a 7-cm balloon
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PDT using a 5-cm balloon
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PDT
Number of subjects: 60
Study: 9006746

Group type: COMPARATOR
Intervention: Placebo (oral, twice daily on days 2-6)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg oral, twice daily on days 2/3 followed by placebo on days 4-6)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg oral, twice daily on days 2-6)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg oral, twice daily) plus Dexamethasone (4 mg oral, twice daily on days 2-6)
Number of subjects: 640
Study: 31210529

Group type: EXPERIMENTAL
Intervention: Tofogliflozin 20 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ipragliflozin 50 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tofogliflozin and Ipragliflozin (both added to sulfonylureas)
Number of subjects: 30
Study: 29582237

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg BID (D150)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg BID (D110)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Dabigatran (both doses)
Number of subjects: 546
Study: 27436584

Group type: COMPARATOR
Intervention: C - cycling at 171 ± 6 W for 60 min (control)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: A - cycling at 171 ± 6 W for 60 min, with addition of intermittent arm exercise (98 ± 4 W)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: DS - cycling at 171 ± 6 W interspersed by 30 sec sprints (513 ± 19 W) every 10 min
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: CS - cycling at 171 ± 6 W for 40 min followed by 20 min of six 30 sec sprints (clustered sprints)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: All protocols
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: CS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: DS
Number of subjects: 4
Study: 24725442

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 22172468

Group type: EXPERIMENTAL
Intervention: Trehalose (TRE)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isomaltulose (IMU)
Number of subjects: 10
Study: 18847418

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium compounds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevelamer (in patients older than 65 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paricalcitol and cinacalcet
Number of subjects: 0
Study: 16944295

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 682

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 682
Study: 12692805

Group type: EXPERIMENTAL
Intervention: Tube Feeding (TF)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 34
Study: 10871712

Group type: EXPERIMENTAL
Intervention: MDMA (1.5 mg/kg p.o.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Haloperidol (1.4 mg i.v.)
Number of subjects: 14
Study: 9347436

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.04 mg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tramadol 0.6 mg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8471816

Group type: EXPERIMENTAL
Intervention: Combined preoperative treatment (group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chemotherapy alone (group 2)
Number of subjects: 20
Study: 3954130

Group type: EXPERIMENTAL
Intervention: 15 mm diameter resistor
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Decreasing aperture size from 15 mm to 6 mm
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Decreasing aperture size from 6 mm to 5 mm
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Throughout the study
Number of subjects: 15
Study: 29177975

Group type: COMPARATOR
Intervention: Trabectedin 0.58 or 0.9 mg/m2 (Study #1004)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Trabectedin 1.5 mg/m2 by 24-h IV infusion every 3 weeks (Study #3007)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Grade 3-4 hepatotoxicity (Study #3007)
Number of subjects: 6
Study: 28029926

Group type: EXPERIMENTAL
Intervention: n‐3 LCPUFA (fish oil) 2.4 g per day
Number of subjects: 736

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: n‐3 LCPUFA (fish oil)
Number of subjects: 736
Study: 24970858

Group type: EXPERIMENTAL
Intervention: DHA supplementation (2,000 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (identical soy/corn oil capsules)
Number of subjects: 55
Study: 22861493

Group type: EXPERIMENTAL
Intervention: Patient interviews
Number of subjects: 155

Group type: COMPARATOR
Intervention: Medication and clinical records
Number of subjects: 155
Study: 20487083

Group type: EXPERIMENTAL
Intervention: Delirium Abatement Program (DAP)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 457
Study: 18318945

Group type: COMPARATOR
Intervention: Amoxicillin (oral, twice daily for 5 days)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (intramuscular, once daily for 2 days)
Number of subjects: 458
Study: 16704037

Group type: EXPERIMENTAL
Intervention: TB treatment for 4 months under direct observation after 2 months of initial treatment
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Risk factors identified through Cox multivariate regression analysis
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Presence of multiple independent risk factors
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Extent of disease and treatment failure/relapse
Number of subjects: 1075
Study: 14995060

Group type: EXPERIMENTAL
Intervention: GSM mobile phone with speaker disabled and configured to transmit at full‐radiated power
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Non‐modified GSM mobile phone in active standby mode
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham exposures
Number of subjects: 10
Study: 10965418

Group type: EXPERIMENTAL
Intervention: benidipine (4 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 8975685

Group type: EXPERIMENTAL
Intervention: Manipulations of participants' processing goals in Experiments 1 and 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulations of participants' processing goals in Experiment 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACME model simulation
Number of subjects: 0
Study: 1335646

Group type: EXPERIMENTAL
Intervention: Combination of immune globulin (Ig) and hepatitis A vaccine
Number of subjects: 149

Group type: COMPARATOR
Intervention: Hepatitis A vaccine alone
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Combination of Ig and vaccine
Number of subjects: 149
Study: 6205489

Group type: EXPERIMENTAL
Intervention: 2SHT/10HT
Number of subjects: 201

Group type: COMPARATOR
Intervention: 2SHRZ/10HT
Number of subjects: 201
Study: 28474341

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg, n = 40
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo, n = 40
Number of subjects: 80
Study: 27920484

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) screening
Number of subjects: 14294

Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT) screening
Number of subjects: 14294

Group type: COMPARATOR
Intervention: Control group (individuals not invited to screening)
Number of subjects: 14294
Study: 25335434

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (IVTA)
Number of subjects: 33
Study: 23951270

Group type: EXPERIMENTAL
Intervention: SHARP-at work intervention (2-day training in problem solving intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 20640584

Group type: EXPERIMENTAL
Intervention: Repetitive nerve blocks with lidocain, corticosteroids and hyaluronic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tailored surgical neurectomy
Number of subjects: 0
Study: 18574679

Group type: EXPERIMENTAL
Intervention: Intensive intervention (physician advice, in-person counseling with nicotine replacement therapy, 5 telephone calls)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Minimal intervention (physician advice and self-help manual)
Number of subjects: 464
Study: 17043424

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (intravenous cefotaxime 2 g q 8 hr for 7 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: On-demand antibiotics (same antibiotics only when infection became evident)
Number of subjects: 120
Study: 14981967

Group type: EXPERIMENTAL
Intervention: Hematopoietic growth factor-mobilized donor progenitor cells from peripheral blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative conditioning regimens prior to SCT
Number of subjects: 0
Study: 11115306

Group type: EXPERIMENTAL
Intervention: Ventolin HFA
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ventolin CFC
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 7494588

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy in patients with preinfarction angina
Number of subjects: 23

Group type: COMPARATOR
Intervention: Thrombolytic therapy in patients without preinfarction angina
Number of subjects: 23
Study: 1387927

Group type: EXPERIMENTAL
Intervention: Single intravenous dose of ondansetron (8-32 mg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Single 8 mg i.v. dose of ondansetron
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Single 32 mg i.v. dose of ondansetron
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ondansetron dosing regimen (8-32 mg i.v. followed by 8 mg orally twice daily)
Number of subjects: 3
Study: 3993321

Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg intravenously given at least 90 min before premedication
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 31189511

Group type: EXPERIMENTAL
Intervention: Dulaglutide (1.5 mg weekly subcutaneous injection)
Number of subjects: 9901

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9901

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 9901
Study: 28676085

Group type: EXPERIMENTAL
Intervention: 1 mg of NeuroEPO every 8 hours for 4 days (Group A)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.5 mg of NeuroEPO every 8 hours for 4 days (Group B)
Number of subjects: 25
Study: 25584931

Group type: EXPERIMENTAL
Intervention: IR/ER HB/APAP 45/1950 mg (intact)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: IR/ER HB/APAP 22.5/975 mg (intact)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Crushed IR/ER HB/APAP 45/1950 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intact IR/ER HB/APAP
Number of subjects: 52
Study: 23461723

Group type: EXPERIMENTAL
Intervention: NRP training
Number of subjects: 49

Group type: COMPARATOR
Intervention: No NRP training
Number of subjects: 49
Study: 21813293

Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg (titrated to 100 mg) three times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Glibenclamide 2.5 mg (titrated to 5.0 mg) three times daily
Number of subjects: 40
Study: 19359034

Group type: EXPERIMENTAL
Intervention: Encouragement to enroll in a health-insurance programme and upgraded medical facilities.
Number of subjects: 32515
Study: 16682542

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (TT) - 200 mg/mL of testosterone enanthate every 2 weeks for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo - isotonic sodium chloride solution injections
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Long-term open-label TT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (TT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TT group
Number of subjects: 30
Study: 14707586

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study: 11369986

Group type: EXPERIMENTAL
Intervention: Modified fluid gelatin (1000 ml)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (1000 ml)
Number of subjects: 34
Study: 9160527

Group type: EXPERIMENTAL
Intervention: Single booster dose of rabies vaccine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rabies vaccine (HDCV)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Rabies vaccine (PCECV, PDEV, PVRV)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rabies neutralizing antibody
Number of subjects: 44
Study: 7965290

Group type: EXPERIMENTAL
Intervention: Orthomet screws
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ace screws
Number of subjects: 25
Study: 3117982

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Enteral nutrition (EN)
Number of subjects: 51
Study: 29320378

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 27146963

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg lozenge
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 204
Study: 24524385

Group type: EXPERIMENTAL
Intervention: 3W program (worksite management intervention)
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1207
Study: 23070101

Group type: EXPERIMENTAL
Intervention: Uterine Artery Embolization (UAE)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Myomectomy
Number of subjects: 157
Study: 20462569

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Preference match
Number of subjects: 106
Study: 18252894

Group type: EXPERIMENTAL
Intervention: Diet plus exercise (n = 9)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diet only (n = 7)
Number of subjects: 16
Study: 16607924

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 1 year
Number of subjects: 105
Study: 14606783

Group type: EXPERIMENTAL
Intervention: Conventional inferior alveolar nerve block with needle bevel oriented away from the mandibular ramus
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Bidirectional-needle-rotation technique using the Wand II anesthesia system
Number of subjects: 64
Study: 11001241

Group type: EXPERIMENTAL
Intervention: Pindolol (2.5 mg three times daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9003110

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day, n = 151)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo (n = 154)
Number of subjects: 305
Study: 1468283

Group type: EXPERIMENTAL
Intervention: 10 mg of oral GP (glipizide) taken without food after 4 weeks of OD therapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10 mg of oral GB (glyburide) taken without food after 4 weeks of OD therapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10 mg of oral GP taken without food after 4 weeks of TD therapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10 mg of oral GB taken without food after 4 weeks of TD therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 14
Study: 6138597

Group type: EXPERIMENTAL
Intervention: Metronidazole (250 mg four times a day for 10 days)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Vancomycin (500 mg four times a day for 10 days)
Number of subjects: 101
Study: 29749803

Group type: EXPERIMENTAL
Intervention: Laycarer prepares, labels and stores injections
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Registered nurse prepares injections
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pharmacist prepares injections
Number of subjects: 93

Group type: COMPARATOR
Intervention: Laycarer preparation vs nurse or pharmacist preparation
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Experience with injecting
Number of subjects: 93
Study: 27274999

Group type: EXPERIMENTAL
Intervention: Docetaxel plus Personalized Peptide Vaccination (PPV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel plus Placebo
Number of subjects: 0
Study: 24993352

Group type: EXPERIMENTAL
Intervention: Treadmill Desk Group
Number of subjects: 41
Study: 19928392

Group type: EXPERIMENTAL
Intervention: Thermal infrared imaging (TIRI)
Number of subjects: 27
Study: 15853281

Group type: EXPERIMENTAL
Intervention: Experiential-teaching method entitled 'To be Touched by AIDS' with an affective component involving an African-American female who is an HIV-Positive intravenous drug user.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional lecture and discussion method.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Experiential-teaching method.
Number of subjects: 70
Study: 11680552

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 0
Study: 9559600

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg i.v. three times daily for 5 days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 41
Study: 7889608

Group type: EXPERIMENTAL
Intervention: Prolonged dopamine infusion (5 micrograms/kg/min i.v.) for 83-296 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Brief dopamine infusion (5 micrograms/kg/min i.v.) for 15-21 hours
Number of subjects: 12
Study: 3062558

Group type: EXPERIMENTAL
Intervention: Low protein formula (F1.3) containing 1.3 g protein/100 ml
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High protein formula (F1.8) containing 1.8 g protein/100 ml
Number of subjects: 20

Group type: COMPARATOR
Intervention: Breast-fed (BF)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low protein formula (F1.3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High protein formula (F1.8)
Number of subjects: 20
Study: 11277602

Group type: EXPERIMENTAL
Intervention: Clomipramine (mean dose 89.1 +/- 8.2 mg/day)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Clomipramine maintenance treatment (full doses for 4-6 months)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo substitution after tapering clomipramine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Clomipramine discontinuation
Number of subjects: 81
Study: 31269902

Group type: EXPERIMENTAL
Intervention: Medical records
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Patient self-administered questionnaires (SAQs)
Number of subjects: 759
Study: 30143567

Group type: EXPERIMENTAL
Intervention: Supplementation for moderate acute malnutrition
Number of subjects: 0
Study: 27256731

Group type: EXPERIMENTAL
Intervention: High lead exposure group (cord blood lead >0.48 μmol/L)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (cord blood lead <0.48 μmol/L)
Number of subjects: 120
Study: 25230290

Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir (PrEP)
Number of subjects: 470
Study: 23017356

Group type: EXPERIMENTAL
Intervention: 4 g n3-FA/day
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: COMPARATOR
Intervention: H(2)O (control)
Number of subjects: 53
Study: 20931547

Group type: EXPERIMENTAL
Intervention: Pluvio® (a combination of plant extracts including avocado and soya oil, and a high dose of Urtica Dioica)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 0